85,960 results match your criteria Thromboembolism

Call for Formalized Pathways in Vascular Medicine Training: JACC Review Topic of the Week.

J Am Coll Cardiol 2022 May;79(21):2129-2139

Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

The burden of vascular diseases and complexity of their management have been growing. Vascular medicine specialists may help to bridge gaps in care, especially as part of multidisciplinary teams. However, there is a limited number of vascular medicine specialists because of constraints in training. Read More

View Article and Full-Text PDF

Joint effect of multiple prothrombotic genotypes and mean platelet volume on the risk of incident venous thromboembolism.

Thromb Haemost 2022 May 26. Epub 2022 May 26.

Thrombosis Research Center, Department of Clinical Medicine, UiT - The Arctic University of Norway, Tromsø, Norway.

Background: A high mean platelet volume (MPV), a marker of increased platelet reactivity, is a risk factor for venous thromboembolism (VTE). Whether established prothrombotic single nucleotide polymorphisms (SNPs) further increase the VTE risk in subjects with high MPV because of biological interaction remains unknown.

Aim: To investigate the joint effect of high MPV and prothrombotic genotypes, comprising a 5-SNP genetic risk score (GRS), on the risk of VTE in a population-based case-cohort. Read More

View Article and Full-Text PDF

Factor V Leiden: Development of VTE in Surgery and Trauma Patients: A Systematic Review.

Dimens Crit Care Nurs 2022 Jul-Aug 01;41(4):190-199

Background: Factor V Leiden (FVL) is a hereditary thrombophilia, which causes the blood to be more hypercoagulable; in essence, the blood tends to clot more easily, especially under certain circumstances. It is the most common genetic mutation, causing thrombophilia in patients of white background. Patients that have FVL are at a higher risk to develop venous thromboembolism (VTE) after surgery and trauma. Read More

View Article and Full-Text PDF

Venous Thromboembolism Prophylaxis in Hospitalized Sickle Cell Disease and Sickle Cell Trait Patients.

Eur J Haematol 2022 May 26. Epub 2022 May 26.

Department of Hematology-Oncology, Beaumont Health System, Royal Oak, OUWB School of Medicine, MI, USA.

Introduction: Sickle trait (Hb SA) or sickle disease (Hb SS) carry increased risk of venous thromboembolism (VTE). Hb SS patients are young and lack common comorbid conditions that qualify them for VTE prophylaxis (VTEP).

Methods: Retrospective, multi-center analysis of Hb SS/Hb SA adult patients between January 2013 and December 2018. Read More

View Article and Full-Text PDF

Thromboembolic Risk in Patients With Pneumonia and New-Onset Atrial Fibrillation Not Receiving Anticoagulation Therapy.

JAMA Netw Open 2022 May 2;5(5):e2213945. Epub 2022 May 2.

Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, Aalborg, Denmark.

Importance: New-onset atrial fibrillation (AF) is commonly reported in patients with severe infections. However, the absolute risk of thromboembolic events without anticoagulation remains unknown.

Objective: To investigate the thromboembolic risks associated with AF in patients with pneumonia, assess the risk of recurrent AF, and examine the association of initiation of anticoagulation therapy with new-onset AF. Read More

View Article and Full-Text PDF

Whole blood samples for faster real-time PCR analysis of thrombophilic mutations in SARS-CoV-2 virus positive patients.

Physiol Res 2022 May 26. Epub 2022 May 26.

Institute of Clinical Biochemistry and Diagnostics, Charles University Hospital, Hradec Králové, Czech Republic.

High incidence of thrombosis and venous thromboembolism was reported in patients with COVID-19. In this study, we focused on analysis of thrombophilic mutations performed without a standard DNA extraction step. In one hundred of COVID-19 positive outpatients, real-time PCR for Leiden mutation in the FV gene and G20210A mutation in the FII gene was carried out from DNA extracts and modified whole blood samples, and their cycle threshold (Ct) values were evaluated. Read More

View Article and Full-Text PDF

Maternal Health: The Mirror of Our Healthcare System.

Indian J Crit Care Med 2021 Dec;25(Suppl 3):S187-S188

Department of Critical Care Medicine, Manipal Hospital, Dwarka, New Delhi, India.

Krishna B, Kulkarni AP, Srinivasan S. Maternal Health: The Mirror of Our Healthcare System. Indian J Crit Care Med 2021;25(Suppl 3):S187-S188. Read More

View Article and Full-Text PDF
December 2021

Thromboembolic events in left ventricular non-compaction: comparison between children and adults - a systematic review and meta-analysis.

Open Heart 2022 May;9(1)

Department of Pediatrics, International University of Health and Welfare, Otawara, Japan.

Objective: Left ventricular non-compaction (LVNC) is morphologically characterised by excessive trabeculations and deep recesses in the ventricular wall. The risk of thromboembolic disease in the paediatric patients with LVNC has not been clearly established. We conducted this systematic review to evaluate the prevalence and incidence of thromboembolism (TE) in paediatric and adult patients with LVNC and searched for risk factors for TE to explore management strategies. Read More

View Article and Full-Text PDF

Tissue Factor Pathway Inhibitor 2: A Novel Biomarker for Predicting Asymptomatic Venous Thromboembolism in Patients with Epithelial Ovarian Cancer.

Gynecol Obstet Invest 2022 May 25:1-8. Epub 2022 May 25.

Department of Obstetrics and Gynecology, Nara Medical University, Kashihara, Japan.

Objectives: Patients with asymptomatic venous thromboembolism (VTE) are associated with an increased risk of pulmonary thromboembolism events. However, due to low specificity and high false-positive rates, D-dimer testing cannot be used alone to diagnose VTE. Tissue factor pathway inhibitor 2 (TFPI2), a new serodiagnostic marker for ovarian cancer, plays a role in blood coagulation system regulation. Read More

View Article and Full-Text PDF

Survival outcomes with warfarin compared with direct oral anticoagulants in cancer-associated venous thromboembolism in the United States: A population-based cohort study.

PLoS Med 2022 May 25;19(5):e1004012. Epub 2022 May 25.

Division of Hematology and Division of Hemostasis and Thrombosis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America.

Background: Direct oral anticoagulants (DOACs) have comparable efficacy with low-molecular-weight heparin (LMWH) for the treatment of cancer-associated venous thromboembolism (VTE). Whether there is a mortality benefit of DOACs compared with warfarin in the management of VTE in cancer is not established.

Methods And Findings: Utilizing the United States' Surveillance, Epidemiology, and End Results (SEER)-Medicare linked databases from 2012 through 2016, we analyzed overall survival in individuals diagnosed with a primary gastric, colorectal, pancreas, lung, ovarian, or brain cancer and VTE who received a prescription of DOAC or warfarin within 30 days of VTE diagnosis. Read More

View Article and Full-Text PDF

Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS Trial.

JAMA Cardiol 2022 May 25. Epub 2022 May 25.

Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.

Importance: Data are limited regarding the risk of cerebrovascular ischemic events and major bleeding in patients with atrial fibrillation (AF) and recent acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI).

Objective: Determine the efficacy and safety of apixaban or vitamin K antagonists (VKA) and aspirin or placebo according to prior stroke, transient ischemic attack (TIA), or thromboembolism (TE).

Design, Setting, And Participants: In this prospective, multicenter, 2-by-2 factorial, randomized clinical trial, post hoc parallel analyses were performed to compare randomized treatment regimens according to presence or absence of prior stroke/TIA/TE using Cox proportional hazards models. Read More

View Article and Full-Text PDF

Unanswered questions in cancer-associated thrombosis.

Br J Haematol 2022 May 25. Epub 2022 May 25.

Division of Hematology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada.

Cancer-associated venous thromboembolism (VTE) is a leading cause of morbidity and mortality in patients with cancer. Treatment of cancer-associated VTE comes with a heightened risk of anticoagulant-related bleeding that differs by choice of anticoagulant as well as by patient- and disease-specific risk factors. Available data from randomized controlled trials and observational studies in cancer-associated VTE suggest that direct oral anticoagulants are effective, continuing anticoagulation beyond six months is indicated in those with active cancer and that patients who develop 'breakthrough' thrombotic events can be effectively treated. Read More

View Article and Full-Text PDF

Factors and Outcomes Associated With Venous Thromboembolism Following Bariatric Surgery.

Am Surg 2022 May 25:31348221103645. Epub 2022 May 25.

Cardiovascular Outcomes Research Laboratories (CORELAB), David Geffen School of Medicine, 12222University of California, Los Angeles, CA, USA.

Background: The present national study characterized the incidence and factors associated with VTE following bariatric operations and its association with postoperative outcomes and resource use.

Methods: Adults (18 years) undergoing elective sleeve gastrectomy or gastric bypass (laparoscopic and open) were identified in the 2016-2018 Nationwide Readmissions Database. International Classification of Diseases 10th Revision codes for deep venous thrombosis and/or pulmonary embolism were used to ascertain the presence of VTE. Read More

View Article and Full-Text PDF

Cerebrovascular Events in Pediatric Inflammatory Bowel Disease: A Review of Published Cases.

Pediatr Gastroenterol Hepatol Nutr 2022 May 9;25(3):180-193. Epub 2022 May 9.

Research Institute for Gastroenterology and Liver Disease, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Pediatric inflammatory bowel disease (PIBD) is a multisystem disorder characterized by intestinal and extraintestinal manifestations and complications. Cerebrovascular events (CVE) are rare extraintestinal complications in patients with PIBD. Statistics show that 3. Read More

View Article and Full-Text PDF

Thromboembolism and bleeding in patients with atrial fibrillation and liver disease - a nationwide register-based cohort study: Thromboembolism and bleeding in liver disease.

Clin Res Hepatol Gastroenterol 2022 May 21:101952. Epub 2022 May 21.

Department of Cardiology, Aalborg University Hospital, Denmark; Unit of Clinical Biostatistics and Epidemiology, Aalborg University Hospital, Denmark.

Background: Balancing the risk of thromboembolism and bleeding in patients with liver disease and atrial fibrillation/flutter is particularly challenging.

Purpose: To examine the risks of thromboembolism and bleeding with use/non-use of oral anticoagulation (including vitamin K-antagonists and direct oral anticoagulants) in patients with liver disease and AF.

Methods: Danish nationwide register-based cohort study of anticoagulant naive individuals with liver disease, incident atrial fibrillation/flutter, and a CHA2DS2-VASc-score≥1 (men) or ≥2 (women), alive 30 days after atrial fibrillation/flutter diagnosis. Read More

View Article and Full-Text PDF

Utility of Thromboelastography and velocity curve derivative in diagnosing COVID-19 associated coagulopathy.

Int J Lab Hematol 2022 May 24. Epub 2022 May 24.

Department of Critical Care Medicine, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, Karnataka, India.

Background: COVID-19 associated coagulopathy (CAC) can either be localized or systemic hypercoagulable state with increased risk of thromboembolism. This study looked into the usefulness of Thromboelastography (TEG) and the velocity curve (V-curve) derivative from TEG in diagnosing and differentiating different stages of CAC.

Materials And Methods: A prospective single cohort study of RT-PCR confirmed COVID-19 patients was carried out for 2 weeks. Read More

View Article and Full-Text PDF

Lower-leg injury and knee arthroscopy have distinct effects on coagulation.

Blood Adv 2022 May 24. Epub 2022 May 24.

Leiden University Medical Center, Leiden, Netherlands.

Lower-leg injury and knee arthroscopy are associated with increased venous thromboembolism (VTE) risk. It is unknown how these conditions affect coagulation. To study the effect of 1) lower-leg trauma and 2) knee arthroscopy on coagulation. Read More

View Article and Full-Text PDF

Risk stratification for hospital-acquired venous thromboembolism in medical patients (RISE): Protocol for a prospective cohort study.

PLoS One 2022 24;17(5):e0268833. Epub 2022 May 24.

Division of Internal Medicine, Department of Medicine, Lausanne University Hospital (CHUV), Lausanne, Switzerland.

Background: Hospital-acquired venous thromboembolism (VTE) is one of the leading preventable causes of in-hospital mortality. However, its risk assessment in medically ill inpatients is complicated due to the patients' heterogeneity and complexity of currently available risk assessment models (RAMs). The simplified Geneva score provides simplicity but has not yet been prospectively validated. Read More

View Article and Full-Text PDF

Right ventricular dysfunction in patients with COVID-19 pneumonitis whose lungs are mechanically ventilated: a multicentre prospective cohort study.

Anaesthesia 2022 May 24. Epub 2022 May 24.

Department of Anaesthesia, Golden Jubilee National Hospital, Clydebank, UK.

Cardiovascular complications due to COVID-19, such as right ventricular dysfunction, are common. The combination of acute respiratory distress syndrome, invasive mechanical ventilation, thromboembolic disease and direct myocardial injury creates conditions where right ventricular dysfunction is likely to occur. We undertook a prospective, multicentre cohort study in 10 Scottish intensive care units of patients with COVID-19 pneumonitis whose lungs were mechanically ventilated. Read More

View Article and Full-Text PDF

Risk Factor Analysis of Venous Thromboembolism in Cancer: A National Inpatient Sample Study.

Cureus 2022 Apr 20;14(4):e24323. Epub 2022 Apr 20.

Internal Medicine, Pikeville Medical Center, Pikeville, USA.

Objective In this study, we aimed to explore the association of demographic characteristics and comorbidities with the risk of venous thromboembolism (VTE) in cancer inpatients, as well as to delineate the mortality risk in cancer inpatients with VTE. Methods We conducted a retrospective cohort analysis based on the National Inpatient Sample (NIS) 2012-2014, involving 339,395 inpatients with a primary diagnosis of cancer subdivided into cohorts without VTE (n=331,695) and with VTE (n=7,700). We used a binomial logistic regression model to evaluate the odds ratio (OR) of demographics, comorbidities, and in-hospital mortality rate with respect to cancer inpatients with VTE. Read More

View Article and Full-Text PDF

Prophylactic Unfractionated Subcutaneous Heparin Does Not Increase Postoperative Hemorrhage in Elderly Patients Undergoing Emergency Neurosurgical Procedures.

Cureus 2022 Apr 20;14(4):e24324. Epub 2022 Apr 20.

General Surgery, Northwell Health, New York City, USA.

Purpose The purpose of this study is to evaluate the impact in the development of intracerebral hemorrhage in elderly critically ill patients who received prophylactic subcutaneous unfractionated heparin (SCUFH) less than 24 hours after undergoing emergency neurosurgery.  Methods A retrospective analysis was performed on patients who underwent emergency neurosurgery and were admitted to the surgical intensive care unit (SICU) at a tertiary care center over a 10-year period. Administration of prophylactic SCUFH within 24 hours of neurosurgery was required for inclusion. Read More

View Article and Full-Text PDF

Duplication of the inferior vena cava: a case series.

J Int Med Res 2022 May;50(5):3000605221100771

Department of Vascular Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.

The inferior vena cava (IVC) may develop abnormally because of its complex embryogenesis. An understanding of congenital variants such as duplication of the IVC is essential for clinical interventions, particularly those performed by surgeons and radiologists. We herein describe five patients who were diagnosed with duplication of the IVC by computed tomography or angiography and summarize their imaging and clinical features. Read More

View Article and Full-Text PDF

Safety and effectiveness of nivolumab in Japanese patients with malignant melanoma: Final analysis of a post-marketing surveillance.

J Dermatol 2022 May 23. Epub 2022 May 23.

Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.

Nivolumab, a monoclonal antibody against human programmed death 1, was approved for the treatment of melanoma in July 2014 in Japan. Because the Japanese phase II studies (ONO-4538-02, ONO-4538-08) enrolled small numbers of melanoma patients, post-marketing surveillance (PMS; JapicCTI-163 272) was conducted to collect safety data in a larger patient population. We report data for melanoma patients who received nivolumab between July 4, 2014 and February 28, 2017. Read More

View Article and Full-Text PDF

Risk of venous thromboembolism in men with prostate cancer compared with men in the general population: a nationwide population-based cohort study in Sweden.

BMJ Open 2022 May 23;12(5):e055485. Epub 2022 May 23.

Integrated Evidence Generation, Bayer AB, Stockholm, Sweden.

Objective: To estimate the additional risk of venous thromboembolism (VTE) in men with prostate cancer compared with men without prostate cancer in Sweden.

Design: Nationwide cohort study following 92 105 men with prostate cancer and 466 241 men without prostate cancer (comparison cohort) matched 5:1 by birth year and residential region.

Setting: The male general population of Sweden (using the Nationwide Prostate Cancer data Base Sweden). Read More

View Article and Full-Text PDF

Beyond fibrinolysis: The confounding role of Lp(a) in thrombosis.

Michael B Boffa

Atherosclerosis 2022 May;349:72-81

Department of Biochemistry and Robarts Research Institute, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, Ontario, Canada. Electronic address:

Elevated plasma concentrations of lipoprotein(a) (Lp(a)) are a causal risk factor for the development of atherothrombotic disorders including coronary heart disease. However, the pathological mechanisms underlying this causal relationship remain incompletely defined. Lp(a) consists of a lipoprotein particle in which apolipoproteinB100 is covalently linked to the unique glycoprotein apolipoprotein(a) (apo(a)). Read More

View Article and Full-Text PDF

Venous sinus thrombosis after the first dose of Pfizer BioNTech vaccine.

BMJ Case Rep 2022 May 20;15(5). Epub 2022 May 20.

General Internal Medicine, Northampton General Hospital NHS Trust, Northampton, UK.

mRNA vaccines including Pfizer BioNTech and Moderna have categorically been considered safe when it comes to preventing COVID-19. However, there is still a small associated risk of thromboembolic phenomenon including venous sinus thrombosis with it and our case report highlights one.We describe a patient who developed severe progressive headache, tinnitus and visual disturbance symptoms post-Pfizer-SARS-CoV-2 vaccination. Read More

View Article and Full-Text PDF

Pulmonary Embolism at Extreme High Altitude: A Study of Seven Cases.

High Alt Med Biol 2022 May 23. Epub 2022 May 23.

Department of Respiratory Disease, General Hospital of Xinjiang Military Command, Urumqi, China.

Wu, Jialin, Xiaobo Han, Haiwen Ke, Li Wang, Kun Wang, Jianli Zhang, Jun Tang, Wei Yan, Guangjun Wang, and Peng Jiang. Pulmonary embolism at extreme high altitude: A study of seven cases. XX:000-000, 2022. Read More

View Article and Full-Text PDF

SARS-CoV-2 Infection Dysregulates Host Iron (Fe)-Redox Homeostasis (Fe-R-H): Role of Fe-Redox Regulators, Ferroptosis Inhibitors, Anticoagulants, and Iron-Chelators in COVID-19 Control.

J Diet Suppl 2022 May 22:1-60. Epub 2022 May 22.

N-terminus Research Laboratory, Yorba Linda, CA, USA.

Severe imbalance in iron metabolism among SARS-CoV-2 infected patients is prominent in every symptomatic (mild, moderate to severe) clinical phase of COVID-19. - correlates with reduced O transport by erythrocytes, overexpression of HIF-1α, altered mitochondrial bioenergetics with host metabolic reprogramming (HMR). results from an increased iron overload, which triggers a fulminant proinflammatory response - the acute cytokine release syndrome (CRS). Read More

View Article and Full-Text PDF

Activated charcoal can be used to aid the diagnosis of an overdose of dabigatran etexilate.

Int J Clin Pharmacol Ther 2022 May 23. Epub 2022 May 23.

The direct-acting oral anticoagulant dabigatran etexilate (DE prevent systemic thromboembolism and cerebral apoplexy in patients with nonvalvular atrial fibrillation. On September 22, 2021, an 86-year-old female patient in Peking University People's Hospital presented with a severely reduced fibrinogen level and significantly prolonged prothrombin time (PT) and activated partial thromboplastin time (APTT). She had a history of hypertension, hyperlipidemia, arrhythmia, and a 1-year history of taking DE (110 mg, p. Read More

View Article and Full-Text PDF

ANMCO position paper 'Appropriateness of prescribing direct oral anticoagulants in stroke and systemic thromboembolism prevention in adult patients with non-valvular atrial fibrillation'.

Eur Heart J Suppl 2022 May 18;24(Suppl C):C278-C288. Epub 2022 May 18.

Division of Clinical and Rehabilitation Cardiology, Emergency Department, P.O. San Filippo Neri - ASL Roma 1, Via G. Martinotti, 20, 00135, Roma, RM, Italy.

The appropriateness of prescribing direct oral anticoagulants [dabigatran, rivaroxaban, apixaban, and edoxaban (DOACs)] is regulated on the criteria established in Phase III trials. These criteria are reported in the summary of the product characteristics of the four DOACs. In clinical practice, prescriptions are not always in compliance with established indications. Read More

View Article and Full-Text PDF